Evidence map›Paper›PMID 29321561›Full record

ArticleScientific reports2018

Tumor suppressor activity of miR-451: Identification of CARF as a new target.

Ling Li, Ran Gao, Yue Yu, Zeenia Kaul, Jia Wang, Rajkumar S Kalra, Zhenya Zhang, Sunil C Kaul, Renu Wadhwa

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Ling LiDrug Discovery and Assets Innovation Lab, DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), DAICENTER, Biomedical Research Institute, National Institute of Advanced Industrial Science & Technology (AIST), Tsukuba, 305 8565, Japan.
Ran GaoDrug Discovery and Assets Innovation Lab, DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), DAICENTER, Biomedical Research Institute, National Institute of Advanced Industrial Science & Technology (AIST), Tsukuba, 305 8565, Japan.
Yue YuDrug Discovery and Assets Innovation Lab, DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), DAICENTER, Biomedical Research Institute, National Institute of Advanced Industrial Science & Technology (AIST), Tsukuba, 305 8565, Japan.
Zeenia KaulDepartment of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, Ohio, 43210, USA.
Jia WangDrug Discovery and Assets Innovation Lab, DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), DAICENTER, Biomedical Research Institute, National Institute of Advanced Industrial Science & Technology (AIST), Tsukuba, 305 8565, Japan.
Rajkumar S KalraDrug Discovery and Assets Innovation Lab, DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), DAICENTER, Biomedical Research Institute, National Institute of Advanced Industrial Science & Technology (AIST), Tsukuba, 305 8565, Japan.
Zhenya ZhangGraduate School of Life and Environmental Sciences, University of Tsukuba, Tsukuba, Japan.
Sunil C KaulDrug Discovery and Assets Innovation Lab, DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), DAICENTER, Biomedical Research Institute, National Institute of Advanced Industrial Science & Technology (AIST), Tsukuba, 305 8565, Japan. s-kaul@aist.go.jp.
Renu WadhwaDrug Discovery and Assets Innovation Lab, DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), DAICENTER, Biomedical Research Institute, National Institute of Advanced Industrial Science & Technology (AIST), Tsukuba, 305 8565, Japan. renu-wadhwa@aist.go.jp.
National Institute of Advanced Industrial Science and Technology · JPUniversity of Tsukuba · JPThe Ohio State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

microRNAs (miRs) have recently emerged as small non-coding regulators of gene expression. We performed a loss-of-function screening by recruiting retrovirus mediated arbitrary manipulation of genome coupled with escape of cells from 5-Aza-2'-deoxycytidine (5-Aza-dC)-induced senescence. miRNA pool from cells that emerged from 5-Aza-dC-induced senescence was subjected to miR-microarray analysis with respect to the untreated control. We identified miR-451 as one of the upregulated miRs and characterized its functional relevance to drug resistance, cell growth, tumor suppressor proteins p53 and pRb, and stress response. We report that miR-451 caused growth arrest in cells leading to their resistance to 5-Aza-dC-induced senescence. Decrease in cyclin D1, CDK4 and phosphorylated pRB supported the growth arrest in miR-451 transfected cells. We demonstrate that Collaborator of ARF (CARF) protein is a new target of miR-451 that intermediates its function in tumor suppressor and stress signaling.

Indexed as

Up-RegulationA549 CellsAnimalsAzacitidineCell Cycle CheckpointsCell Line, TumorCell ProliferationCell SurvivalDecitabineDNA-Binding ProteinsDrug Resistance, NeoplasmGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMCF-7 CellsMiceAzacitidineCaRF protein, humanDecitabineDNA-Binding ProteinsMicroRNAsMIRN451 microRNA, humanTranscription Factors

Identifiers

PMID29321561
PMCPMC5762681
OpenAlexW2781987324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.